Anti-CD20 monoclonal antibody (rituximab) for the treatment of membranous nephropathy after living-unrelated kidney transplantation: a case report.

[1]  V. Sakhuja,et al.  Recurrent glomerulopathy in the renal allograft. , 2007, Transplantation proceedings.

[2]  L. Gallon,et al.  Anti‐CD20 Monoclonal Antibody (Rituximab) for the Treatment of Recurrent Idiopathic Membranous Nephropathy in a Renal Transplant Patient , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  A. Salama,et al.  Drug Insight: rituximab in renal disease and transplantation , 2006, Nature Clinical Practice Nephrology.

[4]  G. Remuzzi,et al.  Rituximab in idiopathic membranous nephropathy: a one-year prospective study. , 2003, Journal of the American Society of Nephrology : JASN.

[5]  E. Briganti,et al.  Risk of renal allograft loss from recurrent glomerulonephritis. , 2002, The New England journal of medicine.

[6]  L. Racusen,et al.  Plasma cell-rich acute renal allograft rejection. , 1999, Transplantation.

[7]  J. Thistlethwaite,et al.  The recurrence of recurrent membranous glomerulopathy in a renal transplant recipient: case report and literature review. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  L. Truong,et al.  De novo membranous glomerulonephropathy in renal allografts: a report of ten cases and review of the literature. , 1989, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  O. Salvatierra,et al.  DE NOVO AND RECURRENT MEMBRANOUS GLOMERULOPATHY FOLLOWING KIDNEY TRANSPLANTATION , 1983, Transplantation.